PMID- 33973280
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220716
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 36
IP  - 1
DP  - 2022 Feb
TI  - COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights 
      from an analysis of the World Health Organization pharmacovigilance database.
PG  - 199-209
LID - 10.1111/fcp.12695 [doi]
AB  - BACKGROUND: To determine whether the use of disease-modifying antirheumatic drugs 
      (DMARDs) is linked to the risk of COVID-19 among patients with inflammatory 
      rheumatic diseases (IRDs). METHODS: We performed a disproportionality analysis of 
      the World Health Organization pharmacovigilance database between January 1, 2020, 
      and June 10, 2020. The frequency of COVID-19 reports for all DMARD classes 
      identified was compared with that for all other reports for all other drugs and 
      quoted as the reporting odds ratio (ROR) (95% confidence interval [CI]). RESULTS: 
      Among 980,446 individual case-safety reports voluntarily recorded in the 
      database, 398 identified COVID-19 in DMARD-treated patients with IRDs. There were 
      177 (44.5%) patients with rheumatoid arthritis (RA), 120 (30.1%) with ankylosing 
      spondylitis (AS), 93 (23.4%) with psoriatic arthritis (PsA), and 8 (2.0%) with 
      juvenile idiopathic arthritis. Most of the cases of COVID-19 occurred in patients 
      taking anti-TNF agents (84.2%), resulting in a significant disproportionality 
      signal (ROR [95% CI]: 8.31 [7.48-9.23]) - particularly in patients with RA, AS or 
      PsA. A significant inverse disproportionality was found for the anti-IL-6 agent 
      tocilizumab (ROR [95% CI]: 0.12 [0.02-0.88]) and JAK inhibitors (ROR [95% CI]: 
      0.33 [0.19-0.58]) in patients with RA - suggesting that these two drug classes 
      are safer in the context of RA. CONCLUSION: Our results are in line with the 
      literature on a potentially better safety profile for anti-IL-6 agents and JAK 
      inhibitors. The WHO pharmacovigilance data suggest that COVID-19 is significantly 
      more frequent in patients with IRDs treated with TNF inhibitors.
CI  - (c) 2021 Societe Francaise de Pharmacologie et de Therapeutique.
FAU - Dernoncourt, Amandine
AU  - Dernoncourt A
AD  - Department of Internal Medicine, Amiens-Picardie University Medical Center, 
      Amiens, France.
AD  - RECIF, Amiens-Picardie University Medical Center, Amiens, France.
FAU - Schmidt, Jean
AU  - Schmidt J
AD  - Department of Internal Medicine, Amiens-Picardie University Medical Center, 
      Amiens, France.
AD  - RECIF, Amiens-Picardie University Medical Center, Amiens, France.
FAU - Duhaut, Pierre
AU  - Duhaut P
AD  - Department of Internal Medicine, Amiens-Picardie University Medical Center, 
      Amiens, France.
AD  - RECIF, Amiens-Picardie University Medical Center, Amiens, France.
FAU - Liabeuf, Sophie
AU  - Liabeuf S
AD  - Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, 
      France.
AD  - MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
FAU - Gras-Champel, Valerie
AU  - Gras-Champel V
AD  - Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, 
      France.
AD  - MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
FAU - Masmoudi, Kamel
AU  - Masmoudi K
AD  - Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, 
      France.
FAU - Bennis, Youssef
AU  - Bennis Y
AD  - Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, 
      France.
AD  - MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
FAU - Batteux, Benjamin
AU  - Batteux B
AUID- ORCID: 0000-0001-9466-7110
AD  - RECIF, Amiens-Picardie University Medical Center, Amiens, France.
AD  - Department of Clinical Pharmacology, Amiens University Medical Center, Amiens, 
      France.
AD  - MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
AD  - Department of Rheumatology, Saint-Quentin Medical Center, Saint-Quentin, France.
LA  - eng
PT  - Journal Article
DEP - 20210525
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
SB  - IM
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/diagnosis/drug therapy/epidemiology
MH  - *COVID-19
MH  - Humans
MH  - Pharmacovigilance
MH  - SARS-CoV-2
MH  - Tumor Necrosis Factor Inhibitors
MH  - World Health Organization
PMC - PMC8239613
OTO - NOTNLM
OT  - COVID-19
OT  - DMARDs
OT  - Pharmacovigilance database (VigiBase(R))
OT  - inflammatory rheumatic disease
EDAT- 2021/05/12 06:00
MHDA- 2022/01/18 06:00
PMCR- 2021/05/25
CRDT- 2021/05/11 06:49
PHST- 2021/04/09 00:00 [revised]
PHST- 2020/12/16 00:00 [received]
PHST- 2021/05/06 00:00 [accepted]
PHST- 2021/05/12 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/05/11 06:49 [entrez]
PHST- 2021/05/25 00:00 [pmc-release]
AID - FCP12695 [pii]
AID - 10.1111/fcp.12695 [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2022 Feb;36(1):199-209. doi: 10.1111/fcp.12695. Epub 2021 
      May 25.